AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 DEC 10 - (NewsRx.com & NewsRx.net) -- The hepatitis C virus core protein modulates the immune response against the hepatitis B virus surface antigen in mice.
According to recent research published in the journal Biochemical and Biophysical Research Communications, "Mucosal vaccination is currently arousing a great deal of interest, since mucosally induced immunity is able to protect not only against microorganisms using mucosa as a door of entry, but also against those parenterally transmitted. Hepatitis C virus (HCV) is considered a worldwide health problem and a current vaccine is not available."
"In the present work, immunogenicity of particulate HCcAg was evaluated, administered alone and also in formulations with the main protective antigen of HBV, the surface antigen (HBsAg), both by mucosal (i.n.) and parenteral (i.m.) routes," reported Julio C. Aguilar and colleagues at the Center for Genetic Engineering and Biotechnology in Havana, Cuba. "HCcAg was able to induce strong immune responses after nasal as well as parenteral administration, developing a strong Th1-like antibody response in serum. Preliminary data also suggested the ability of HCcAg to efficiently enhance and modulate the host immune response ...
Source: HighBeam Research, HCV core protein modulates immune response against HBV surface...